Designed as true suspension cell line, ProBioGen’s AGE1.CR.pIX platform grows in chemically defined medium and is free of any adventitious agents
ProBioGen has announced Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to develop its lead vaccine. The agreement is the latest in a series of collaborations between the companies, including the development of an efficient manufacturing process for Nobelpharma's viral vaccine.
Designed as true suspension cell line, ProBioGen’s AGE1.CR.pIX platform grows in chemically defined medium and is free of any adventitious agents. This allows cultivation in large bioreactors with reduced lead times and thus a more controlled production process in closed systems, the company says.
Dr Gabriele Schneider, Chief Business Officer at ProBioGen commented: "Cell-based systems for vaccine production offer a cost-effective, efficient and flexible alternative to traditional vaccine production, e. g. on chicken eggs. With the AGE1.CR.pIX, we have created an exceptionally robust and scalable system, which is becoming increasingly important and we are pleased about the increased demand."